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A B S T R A C T
Purpose: The ketogenic diet is an alternative treatment for patients with refractory epilepsy. Most
studies to date report dietary response in children. There are limited data evaluating the efﬁcacy of the
ketogenic diet in adults. This is a report of the long-term outcome in a largely adult population of patients
treated with the ketogenic diet for epilepsy.
Method: Twenty-nine adult and adolescent patients (mean age 32 years, range 11–51) were initiated on
the ketogenic diet and followed until diet discontinuation. Clinical response and adverse effects were
noted during the duration of the diet.
Results: Fifty-two percent of patients had a signiﬁcant reduction in seizure frequency on the ketogenic
diet, including 45% with 50% reduction in seizure frequency. Thirty-one percent had no improvement,
seven percent were unable to successfully initiate the diet, and 10% had a >50% increase in seizure
frequency. The diet was continued for a mean of 9 months (range 0.13–35 months), with ﬁve patients
completing 23 months. There was a trend toward better response and better tolerability/longer
duration in patients with symptomatic generalized epilepsy. The diet was generally well-tolerated, but
undesired weight loss and constipation were the most frequent adverse effects.
Conclusion: The ketogenic diet can be used safely in the adult and adolescent population, with a response
rate similar to those seen in children. Patient with symptomatic generalized epilepsy may be particularly
good candidates for this type of dietary treatment.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The ketogenic diet is an alternative form of treatment for
patients with refractory epilepsy. Approximately 40–67% of
pediatric patients may experience a 50% seizure frequency
reduction, and multiple seizure types may respond.1–3 Only
limited data regarding the utility of the ketogenic diet in adults
are available.4–9 Long-term data regarding the response to the
ketogenic data in adults are lacking at this time.
We report the long-term data on a series of twenty-nine
patients (ages 11–51 years), who were initiated on the ketogenic
diet at the Jefferson Comprehensive Epilepsy Center.* Corresponding author at: Jefferson Comprehensive Epilepsy Center, 901 Walnut
Street, Suite 400, Philadelphia, PA 19107, United States. Tel.: +1 215 955 1222;
fax: +1 215 955 9976.
E-mail address: maromi.nei@jefferson.edu (M. Nei).
http://dx.doi.org/10.1016/j.seizure.2014.02.015
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights re2. Materials and methods
All patients who were initiated on the ketogenic diet for
refractory epilepsy and followed until diet discontinuation at the
Jefferson Comprehensive Epilepsy Center were included. Patients
were placed on the ketogenic diet (ratio of 4 g fat: 1 g combined
carbohydrates and protein) utilizing methods described previous-
ly.5 All diets were initiated in the hospital after an initial period of
fasting for 24–48 h. On-going dietary consultation was provided
through telephone and e-mail. All patients had monitoring of the
complete blood count, liver function tests, lipid panel, electrolytes,
selenium, carnitine, and EKG testing. The maximum duration of
treatment was recommended to be 24 months, due to a concern for
potential complications of a long-term high-fat diet. Antiepileptic
medications were not changed during a minimum of 3 months
after diet initiation. Afterwards, medications changes were made
at the discretion of the patient’s physician.
Seizure type and frequency at baseline was the mean seizure
frequency for each seizure type during the 3 months prior to dietserved.
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recorded at each follow-up evaluation. Dietary compliance was
evaluated through patient and caretaker history and evaluation of
urinary ketones, which were logged daily.
3. Results
3.1. Patients
Twenty-nine patients (16 women, 13 men) with refractory
epilepsy (14 symptomatic generalized, 11 focal, 4 idiopathic
generalized) were initiated on the ketogenic diet. Patients
classiﬁed as having symptomatic generalized epilepsy had
cognitive impairment, generalized tonic–clonic seizures, and a
varied combination of other types of seizures (which included
atypical absence, tonic, atonic, myoclonic, and complex partial)
and generalized epileptiform abnormalities on EEG. All patients
were 17 years at the time of diet initiation, except one (11 years).
The mean age of the patients was 32 years at diet initiation. Each
patient had tried a mean of 6.4 (range 3–16) AEDs and ﬁve had
prior epilepsy surgery. Mean baseline seizure (all types)
frequency was 104 seizures per month (range 0.33–600, SD
167; median 27).Table 1
Patient data.
16 women, 13 men
Age: Mean 32 years (11–51 years)
Epilepsy type:
Idiopathic generalized 
Focal epilepsy 
Symptomatic generalized 
Duration of diet: 
Efﬁcacy
Improvement: (52%) 
Overall improvement, % reduction unclear 
(400 absence seizures/month baseline with daily seizures; on diet had prolonged a
>50% reduction 
Including:
sz-free for 1 year (then difﬁculty with diet compliance) 
sz-free for 3 weeks – unable to tolerate diet further 
1 patient 135 absence sz/month, 8 GTC sz/mo baseline; then absence szs eliminate
40% reduction 
>80% reduction 
No improvement (31%) 
Initial improvement, then no improvement 
Unable to successfully initiate (7%) 
Increased (>50%) seizure frequency > 1 seizure type (10%) 
Reason for discontinuation
Difﬁculty with compliance 
Ineffective 
Fatigue 
Metabolic acidosis 
Lost to follow-up after 4 months 
Weight loss 
Duration 2 years 
Lipids:
Pre-diet (mean) 
Cholesterol 216 mg/dl (120–304, SD 50.8) 
Chol/HDL 4.4 (1.9–8.4, SD 1.8) 
HDL 50.5 mg/dl (33–99, SD 19) All patients transitioned to the ketogenic diet within two to
ﬁve days (mean 2.4 days to ﬁrst positive urinary ketones, SD 2.3)
except for two patients, who were unable to continue the
diet due to a metabolic acidosis in one and abdominal pain
in another. Patients continued the diet for a mean of 9 months
(range 0.13–35 months). Five patients completed 23 months
of the diet. Three patients elected to remain on a high fat
diet after ketogenic diet completion, which included a signiﬁ-
cant but non-uniform increase in dietary protein and carbohy-
drate.
3.2. Response to diet
Fifteen (52%) of patients had a reduction in their seizure
frequency. Thirteen patients (45%) had 50% seizure reduction,
including six (21%) with 80% seizure reduction. Additionally, one
patient with idiopathic generalized epilepsy had a signiﬁcant
decrease in seizure frequency (percent not calculated) with 400
absence seizures/month at baseline. On the diet, she had a 1-h
absence seizure each week.
Nine patients (31%) had no improvement or early diet
discontinuation the diet. Three patients had a 50% increase in
seizure frequency while on the diet, despite compliance and
documentation of 4+ urinary ketones.4
11
14
Mean
9 months (0.13–35 months)
5 completed >23 months (24 months
maximum duration recommended)
3 of these patients on modiﬁed Atkins diet
after 24 months
15 patients
1
bsence seizure (1 h)/week)
13
1
1
d on diet, 5 GTC/month 1
1
6
9 patients
2 patients
2 patients
3 patients
11
9
1
1
1
1
5
Diet discontinuation (mean)
261 mg/dl (123–395, SD 65.2) p = 0.024
5.5 (1.9–10.4, SD 2.1) p = 0.005
48.5 mg/dl (33–109, SD 20.4) p = 0.69
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hospitalization) was generally predictive of long-term response.
For the three patients who remained on a modiﬁed high fat diet
after full ketogenic diet discontinuation, two continued to
experience a >50% reduction in seizure frequency. However,
seizures increased in frequency after transition from the full
ketogenic diet to the modiﬁed diet (in two patients >80% seizure
reduction was reduced to >50% and <80% reduction; the other
patient’s seizure frequency reverted to baseline).
3.3. Response by seizure type
There was a trend (p = 0.11) toward patients with symptomatic
generalized epilepsy having a greater seizure reduction. Sixty-four
percent of individuals with symptomatic generalized epilepsy had
a 50% seizure reduction, and 36% had 80% seizure reduction. For
focal epilepsy, 28% had 50% seizure reduction, with 7%
experiencing a 80% reduction.
3.4. Adverse reactions/complications
Sixteen patients reported adverse effects, and constipation and
undesired weight loss (5 patients each) occurred most. See Table 1
for details. All adverse effects resolved after dietary modiﬁcation or
diet discontinuation.
3.5. Weight
Most individuals lost weight, an average of 7.98 kg (SD 10.6 kg).
In the majority, patients had desired weight loss. In undesired
weight loss (5 patients), caloric adjustments resulted in weight
stabilization.
3.6. Reason for diet discontinuation
The two major reasons for diet discontinuation were difﬁculty
in compliance (11 patients) and lack of efﬁcacy (9 patients). See
Table 1 for details. At 3 months, 62% of remained on the diet. This
declined to 38% by 6 months.
3.7. Lipids
The majority of patients had an increase in total cholesterol and
cholesterol/HDL ratio, but HDL tended to remain stable. See Table 1
for details.
3.8. Carnitine
Three patients had elevated triglyceride levels at the onset of
the diet, which increased further with diet initiation. All three
patients were treated with carnitine supplementation (990–
1980 mg/day) with subsequent reduction in triglycerides (de-
creased from 248 to 161 mg/dl, 310 to 58 mg/dl, and 1071 to
271 mg/dl, respectively), with normalization of the carnitine.
3.9. Other laboratory data
Six of the earlier patients had reductions in serum selenium.
These normalized with selenium supplementation. In later
patients routine selenium supplementation began from the time
of diet initiation, which prevented further selenium depletion.
3.10. EKG and cardiac data
No patient who was on the diet for a minimum of 6 months had
any clinically signiﬁcant EKG abnormality. One patient, whoelected to continue the diet for 23 months, then continued on a
modiﬁed high fat diet, had a normal persantine thallium cardiac
stress test. As previously reported, one patient had a myocardial
infarction ﬁve months after being on the diet for ﬁve months.5
4. Discussion
In this largely adult series of patients, approximately half had a
signiﬁcant reduction in seizure frequency. A favorable short-term
response was generally predictive of long-term seizure control.
The main reasons for diet discontinuation were difﬁculty with
compliance and lack of efﬁcacy. Patients with symptomatic
generalized epilepsy remained on the diet the longest. In select
individuals, continuing the diet beyond 24 months may provide
beneﬁt which might outweigh potential risks of the diet. A small
number experienced more seizures, but it is unclear if this was
directly related to the diet.
While the majority of patients continued the diet for at least 3
months, only a minority (38% of patients) remained on the diet for
at least 6 months. The diet itself was generally well-tolerated.
While the total cholesterol generally increased, the HDL remained
relatively stable. This is in contrast to what has been reported in
some children,10 in whom HDL levels decreased. It is not clear
whether this is represents an age-related difference. While the
trend of lipid changes seen was unfavorable, it is not clear such
changes would cause a signiﬁcant increased risk of atherogenicity
during the duration of the diet. As previously reported,5 there was
one patient with a myocardial infarction. However, this occurred in
the setting of a known pre-existing dyslipidemia (cholesterol 304)
after being on the diet for ﬁve months. Thus it is unclear that the
diet contributed signiﬁcantly toward increasing his risk for a
myocardial infarction. However, after this patient, only patients
with normal baseline lipid proﬁles were treated.
As in children, total carnitine often decreased while triglycer-
ides increased. Carnitine supplementation in these cases resulted
in a reduction in the triglyceride level. The mechanism by which
this occurs is likely similar to that seen during hemodialysis.11
Carnitine regulates mitochondrial free fatty acid transport, and l-
carnitine supplementation may decrease the availability of free
fatty acids for triglyceride synthesis.12
5. Conclusion
While the modiﬁed Atkins diet should be considered ﬁrst-line
dietary therapy, the ketogenic diet is an alternative treatment
which is effective in this age group and may be particularly useful
in symptomatic generalized epilepsy.
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